Eli Lilly will take the spotlight Monday as Wall Street reopens, after Hims & Hers announced it’s pulling its compounded weight-loss pill in response to a U.S. Food and Drug Administration warning. Lilly's shares closed Friday at $1,058.18, rising 3.7%. “No one should be mass-compounding or selling knockoff GLP-1 products regardless of how they’re administered,” a Lilly spokesperson said.